-
Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's Generic Nexium
Tuesday, January 27, 2015 - 10:33am | 148In a report published Tuesday, Deutsche Bank analyst Gregg Gilbert reiterated a Buy rating and $65.00 price target on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). In the report, Deutsche Bank noted, “TEVA announced a final approval for its generic version of Nexium, a $2bn product (reported US...
-
Deutsche Bank, Stifel Differ On Outlook For Eli Lilly
Thursday, January 8, 2015 - 1:46pm | 284Deutsche Bank and Stifel took differing positions on Eli Lilly and Co (NYSE: LLY) Thursday. Analyst Gregg Gilbert at Deutsche Bank downgraded the stock from Buy to Hold and maintained a $75 price target. Gilbert felt the stock had performed well in 2014, but little upside remained. “...
-
UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside
Thursday, January 8, 2015 - 8:32am | 188In a report published Thursday, Deutsche Bank analyst Gregg Gilbert downgraded the rating on Eli Lilly and Co (NYSE: LLY) from Buy to Hold, but reiterated the $75.00 price target. In the report, Deutsche Bank noted, “For a few years we have been contrarian bulls on LLY based on what we...
-
UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On Biopharma
Tuesday, December 2, 2014 - 9:05am | 161In a report published Tuesday, Deutsche Bank analyst Gregg Gilbert initiated coverage on Ligand Pharmaceuticals Inc. (NASDAQ: LGND) with a Buy rating and $74.00 price target. In the report, Deutsche Bank noted, “We are initiating coverage of Ligand with a Buy rating and $74 target price. We view...
-
Deutsche Bank Slashes Price Target On Salix Pharmaceuticals
Monday, November 10, 2014 - 11:04am | 226Deutsche Bank cut its price target Sunday on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) from $134 to $102 and maintained a Hold rating. Analyst Gregg Gilbert noted that "following SLXP’s 3Q miss and disclosures about excessive wholesaler inventory levels for its key products, we...
-
Allergan, Inc Up As Deutsche Bank Initiates Coverage With Buy Rating
Thursday, October 9, 2014 - 6:34am | 235Deutsche Bank initiated coverage of Allergan, Inc (NYSE: AGN) in a report issued Wednesday with a Buy Rating and price target of $215. Analyst Gregg Gilbert viewed Allergan as a “best-in-class Specialty Pharma company, with an attractive combination of strong and sustainable organic...
-
Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline
Wednesday, August 27, 2014 - 11:25am | 400Gregg Gilbert of Deutsche Bank initiated coverage of Pfizer (NYSE: PFE) on Wednesday with a Buy rating and $34 price target. “While Pfizer continues to face headwinds to top-line growth and has a less obviously compelling pipeline relative to some of its peers, we like the company's...
-
UPDATE: Deutsche Bank Initiates Coverage On Merck
Wednesday, August 27, 2014 - 9:17am | 172Deutsche Bank initiated coverage of Merck (NYSE: MRK) with a Hold rating and price target of $63. Analyst Gregg Gilbert outlined reasons for the initiation: Merck has established base businesses, with a track record of returning cash to shareholders. Merck has potential multi-billion...
-
UPDATE: Bank of America Reiterates on AbbVie on Higher HCV Sales
Friday, February 21, 2014 - 11:22am | 125In a report published Friday, Bank of America analyst Gregg Gilbert reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $56.00 to $58.00. In the report, Bank of America noted, “ABBV is unique among the US Major Pharma companies given its significant product...
-
UPDATE: Bank of America Reiterates on Actavis on Possible Forest Acquisition
Wednesday, February 19, 2014 - 10:48am | 192In a report published Wednesday, Bank of America analyst Gregg Gilbert reiterated a Buy rating on Actavis (NYSE: ACT), and raised the price target from $200.00 to $235.00. In the report, Bank of America noted, “We updated our model to reflect ACT's proposed acquisition of Forest (both boards...
-
UPDATE: Shares of Sagent Pharmaceuticals Respond to Bank of America's Upgrade
Friday, February 7, 2014 - 10:39am | 280In a report published Friday, Bank of America Merrill Lynch analyst Gregg Gilbert upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Neutral to Buy and lowered the price target from $26.00 to $25.00 noting favorable risk-reward on the stock's pullback. Gilbert commented on the limited downside if...
-
UPDATE: Bank of America Upgrades Perrigo
Tuesday, January 7, 2014 - 10:07am | 179In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert upgraded Perrigo (NYSE: PRGO) to Buy from Neutral, raising its price objective to $171.00 from $162.00. According to the report, PRGO is the leader in OTC store brands and a strong participant in generic topicals....
-
UPDATE: Bank of America Downgrades Salix Pharmaceuticals, Keeps PO
Tuesday, January 7, 2014 - 9:56am | 169In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert downgraded Salix Pharmaceuticals (NASDAQ: SLXP) to Underperform from Neutral, keeping its $86.00 price objective. According to the report, SLXP's base business has been performing well, led by continued solix...
-
BofA Merrill Lynch Reiterates on AbbVie, Raises PO
Tuesday, December 31, 2013 - 11:03am | 206In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert reiterated a Buy rating on AbbVie (NYSE: ABBV), raising its price target from $53.00 to $56.00. According to the report, in light of recent positive trial results and a survey published by BofA's biotech team,...
-
UPDATE: Bank of America Upgrades Perrigo on Financial Engineering Deal Adding Value
Monday, July 29, 2013 - 5:16pm | 114In a report published on Monday, Bank of America analyst Gregg Gilbert upgraded Perrigo (NYSE: PRGO) from Underperform to Neutral and raised the price target on the company from $116 to $133. In the report, Bank of America stated, "PRGO announced that it will acquire Elan for $8.6bn in cash and...